Video

Dr. Patel on Key Updates from First-Line Trials in NSCLC

Manish Patel, DO, discusses updates in treatment with a PD1 and CTLA-4 inhibitor in non–small cell lung cancer.

Manish Patel, DO, hematologist, oncologist, associate professor of medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota, discusses updates in treatment with a PD1 and CTLA-4 inhibitor in non–small cell lung cancer (NSCLC)

The phase 3 EMPOWER-Lung 3 trial (NCT03409614), studying cemiplimab-rwlc (Libtayo) with chemotherapy, produced positive data similar to the phase 3 KEYNOTE-189 trial (NCT02578680), which evaluated pembrolizumab (Keytruda) plus chemotherapy, Patel explains. Notably, EMPOWER-Lung 3 demonstrated a particular benefit in patients with squamous cell NSCLC, Patel adds.

Additionally, data from the phase 3 POSEIDON trial (NCT03164616) supported the FDA approval of durvalumab (Imfinzi) and tremelimumab-actl (Imjudo) with platinum-based chemotherapy for the treatment of adult patients with metastatic NSCLC without sensitizing EGFR mutations or ALKaberrations, Patel continues. POSEIDON was another example of a trial showing the benefit of treating patients with chemotherapy in combination with a PD-1 inhibitor and CTLA-4 inhibitor, Patel concludes.

Related Videos
YI LIN, MD, PHD
Dr Fakih on the FDA Approval of Sotorasib Plus Panitumumab for KRAS G12C–Mutated mCRC
Al Malki
Ian Krop MD, PhD
Timothy S. Fenske, MD, MS
Ignacio Garrido-Laguna, MD, PhD, MBA
Marwan G. Fakih, MD
Dr Alderuccio on Loncastuximab Tesirine With Rituximab in R/R Follicular Lymphoma
Dr Cascone on Evaluating Neoadjuvant Durvalumab-Based Regimens in Resectable NSCLC
Werutsky